This article is licensed under aCreative Commons Attribution 3.0 Unported Licence.Carolina G. Oliveira, Isolda Romero-Canel ón, Monize M. Silva, James P. C. Coverdale, Pedro Ivo S. Maia, Alzir A. Batista, Silvia Castelli, Alessandro Desideri, Peter J. Sadler, Victor M. Deflon New palladium complexes exhibit potent antiproliferative activity against A2780 and cisplatin-resistant A2780C is human ovarian cancer cells. To cite this article before page numbers are assigned, use the DOI form of citation...
Thu Oct 31, 2019 15:38
Conclusion: Over the years, there was an increasing trend of SRs with these biological drugs. However, it is necessary to continue to develop educational programs in order to get a better reporting system. PMID: 31661986 [PubMed - as supplied by publisher] (Source: Expert Opinion on Drug Safety)
Thu Oct 31, 2019 15:05
In this study, we aimed to explore the role of miR-129-5p in regulating the sensitivity of breast cancer cells to Taxol. Cell apoptosis and autophagy, and the sensitivity of MCF-7 cells to Taxol were assessed with a series of in vitro assays. Our results showed that the inhibition of autophagy increased the Taxol-induced apoptosis and the sensitivity of MCF-7 cells to Taxol. Up-regulation of miR-129-5p also inhibited autophagy and induced apoptosis. Furthermore, miR-129-5p overexpression increased...
Thu Oct 31, 2019 14:56
(Source: Molecular Diagnosis and Therapy)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Thu Oct 31, 2019 00:00
(Source: Molecular Diagnosis and Therapy)
Thu Oct 31, 2019 00:00
Authors: Ozsváth Bíró Nagy Buglyó Sanna Farkas By using various techniques (pH-potentiometry, UV-Visible spectrophotometry, 1H and 17O-NMR, EPR, ESI-MS), first time in the literature, solution equilibrium study has been performed on complexes of dipeptide and tripeptide hydroxamic acids—AlaAlaNHOH, AlaAlaN(Me)OH, AlaGlyGlyNHOH, and AlaGlyGlyN(Me)OH—with 4d metals: the essential Mo(VI) and two half-sandwich type cations, [(η6-p-cym)Ru(H2O)3]2+ as well as [(η5-Cp*)Rh(H2O)3]2+,...
Thu Oct 31, 2019 00:00
Authors: Qin Shu Jianan Wu Qihe Chen As a novel natural compound delivery system, liposomes are capable of incorporating lipophilic bioactive compounds with enhanced compound solubility, stability and bioavailability, and have been successfully translated into real-time clinical applications. To construct the soy phosphatidylcholine (SPC)–cholesterol (Chol) liposome system, the optimal formulation was investigated as 3:1 of SPC to Chol, 10% mannosylerythritol lipid-A (MEL-A) and 1%...
Thu Oct 31, 2019 00:00
This article is protected by copyright. All rights reserved. PMID: 31661723 [PubMed - as supplied by publisher] (Source: The Journal of Physiology)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Tue Oct 29, 2019 00:00
Example: Multiple People At Michigan With Two Fellowships: She then completed her AP/CP residency and fellowship in breast and gynecologic pathology at Duke University in 2017. She also completed a second fellowship in Cancer Biomarker Pathology (with a focus in breast cancer biomarkers) at The University of Texas MD Anderson Cancer Center in 2018. Department of Pathology His training included a residency in Anatomic and Clinical... No other specialty sees residents commonly...
Thu Oct 31, 2019 12:31
I heard a presentation yesterday from Reflexion - they have built an integrated Tomotherapy + PET unit to perform what they call "biologically-directed therapy" or BgRT. I am happy to answer questions about it on this thread. Two things which stood out from the presentation is that the entire concept of BgRT is predicated on two large assumptions (supported by preliminary research but not validated in large trials): 1. SRS/SBRT + Immunotherapy = abscopal effect = better patient endpoints......
Thu Oct 31, 2019 12:03
ConclusionsCombining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system. (Source: The European Journal of Health Economics)MedWorm Message: Have you tried our new medical...
Thu Oct 31, 2019 00:00
CONCLUSION: Oncology nurses play a central role in "brokering" the introduction of early palliative care; this process is supported by their relational proximity to patients and their location "in between" the patient and the oncologist. Training all nurses in palliative care and empowering them to have proactive discussions in a collaborative practice context would allow greater access to early palliative care. PMID: 31659940 [PubMed - as supplied by publisher] (Source: Palliative Medicine)
Tue Oct 29, 2019 00:00
CONCLUSION: This study highlights that adolescent and young adult bone marrow transplant patients are capable of meaningful deliberation about future treatment decisions. Influences on decision-making should be incorporated into advance care planning conversations to facilitate communication between patients and their surrogates. Longitudinal research is needed to explore these influences throughout the trajectory of illness. PMID: 31659933 [PubMed - as supplied by publisher] (Source: Palliative...
Tue Oct 29, 2019 00:00
CONCLUSION: Patients would benefit from comprehensible information on multidrug-resistant bacterial microorganisms. Strategies minimizing social exclusion and emotional impact of multidrug-resistant bacterial microorganisms' diagnosis in end-of-life care are needed as well as adaption or supplementation of standard multidrug-resistant bacterial microorganisms' policies of hospitals. PMID: 31659935 [PubMed - as supplied by publisher] (Source: Palliative Medicine)
Tue Oct 29, 2019 00:00
CONCLUSIONS: This review identified a relatively large number of trials, but with poor and heterogeneous evidence. New clinical recommendations cannot be made based on current evidence. To help provide more definitive trial findings, it may be useful first to understand more about the best way to measure the effectiveness of these therapies in palliative care. PMID: 31659939 [PubMed - as supplied by publisher] (Source: Palliative Medicine)MedWorm Message: Have you tried our new medical search...
Tue Oct 29, 2019 00:00
CONCLUSION: It took 9-10 months for the caregivers' grief, general health and quality of life to correspond to the comparison group. These findings present an opportunity for palliative care research and practice to consider how best to support the majority of caregivers without grief complications so that their pre- and post-death support needs are realised. PMID: 31659934 [PubMed - as supplied by publisher] (Source: Palliative Medicine)
Tue Oct 29, 2019 00:00
CONCLUSION: The implementation of a new hygiene concept is challenging. Despite positive reception of PALLINI from the nurses, ambivalence remained. Addressing these ambivalences may be critical to best implement the new hygiene concept. PMID: 31659938 [PubMed - as supplied by publisher] (Source: Palliative Medicine)
Tue Oct 29, 2019 00:00
Seventy-eight trusts will receive funding for new machines that will improve patient experience and lead to earlier diagnosis. (Source: NHS Networks)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
Thu Oct 31, 2019 00:00
Hundreds of practice nurses across the country have been taught how social media can improve health thanks to the success of one of NHS Digital ’s Widening Digital Participation projects. (Source: NHS Networks)
Thu Oct 31, 2019 00:00
Hundreds of practice nurses trained in how to use social media to improve patients ’ health Related items fromOnMedica Metastatic breast cancer goes undiagnosed for too long NHS must improve access to screening to save lives Cancer strategies failed to improve one-year survival UK cancer survival improved, but lags behind similar nations Cancer diagnosis via screening offers best outcomes (Source: OnMedica Latest News)
Thu Oct 31, 2019 00:00
Authors: de Sena M Pinheiro P, Rodrigues DA, do Couto Maia R, Thota S, Fraga CAM Abstract During the early preclinical phase, from hit identification and optimization to a lead compound, several medicinal chemistry strategies can be used to improve potency and/or selectivity. The conformational restriction is one of these approaches. It consists of introducing some specific structural constraints in a lead candidate to reduce the overall number of possible conformations in order to favor...
Thu Oct 31, 2019 13:53
. (Source: Health Communication)
Thu Oct 31, 2019 00:00
Inflammatory bowel disease (IBD) is a destructive, recurrent, and heterogeneous disease. Its detailed pathogenesis is still unclear, although available evidence supports that IBD is caused by a complex interplay between genetic predispositions, environmental factors, and aberrant immune responses. Recent breakthroughs with regard to its genetics have offered valuable insights into the sophisticated genetic basis, but the identified genetic factors only explain a small part of overall disease variance....
Thu Oct 31, 2019 00:00
The accumulation of lingering senescent cells is an important contributing cause of degenerative aging. In this intriguing report, researchers note that senescent cells resulting from chemotherapy treatment can consume neighboring cells in order to prolong their survival. This is most likely the case for senescent cells in general, whatever their origin. This cellular cannibalism is probably detrimental to tissue function to some small degree, but, since senescent cells are always a tiny minority...
Thu Oct 31, 2019 11:11
Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Leukemia Interventions: Drug: IM JZP-458; Drug: IV JZP-458 Sponsors: Jazz Pharmaceuticals; Children's Oncology Group (COG) Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Wed Oct 30, 2019 17:00
Conditions: Advanced Solid Tumor; Malignant Solid Tumor Intervention: Drug: DS-7300a Sponsor: Daiichi Sankyo Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Non-cutaneous Squamous Cell Carcinoma of Head and Neck Interventions: Drug: ALKS 4230; Drug: Pembrolizumab Sponsors: Alkermes, Inc.; Immune Oncology Network Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Conditions: Lynch Syndrome; Colorectal Cancer; Breast Cancer; Ovarian Cancer; Family Characteristics; Genetic Predisposition Interventions: Other: online cancer risk assessment; Other: Usual care Sponsors: Kaiser Permanente; Patient-Centered Outcomes Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Colorectal Cancer Intervention: Other: Blood Sample Collection Sponsor: Exact Sciences Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Conditions: Ductal Breast Carcinoma In Situ; HER2/Neu Positive Interventions: Biological: Granulocyte-Macrophage Colony-Stimulating Factor; Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC; Procedure: Therapeutic Conventional Surgery Sponsors: Mayo Clinic; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Lung Cancer Interventions: Drug: Erlotinib HCl 150 mg; Drug: Tarceva® Sponsor: Quadras Scientific Solutions Completed (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Conditions: Non Small Cell Lung Cancer; Neoepitopes; Neoantigens; Immunotherapy; Next Generation Sequencing (NGS); Personalized Neoantigen Cancer Vaccine Intervention: Biological: Collection of biopsy (FFPE), blood (PBMC) and stool Sponsors: Ardigen; Małopolskie Centre of Entrepreneurship Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Conditions: Hepatocellular Carcinoma; Liver Cancer; Cholangiocarcinoma Intervention: Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Advanced Non Small Cell Lung Cancer Intervention: Drug: treprilumab combination with platinum-containing dual-drug chemotherapy Sponsor: Yongchang Zhang Recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Condition: Urinary Bladder Neoplasm Intervention: Other: Evaluation of muscle mass and muscle function Sponsors: Rigshospitalet, Denmark; Roche Pharma AG; Merck Sharp & Dohme Corp.; Beckett Foundation; Onkologisk Forskningsfond Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Wed Oct 30, 2019 17:00
Condition: Nasopharyngeal Carcinoma Interventions: Radiation: Carbon-ion radiotherapy; Drug: Camrelizumab; Drug: Apatinib Sponsor: Shanghai Proton and Heavy Ion Center Not yet recruiting (Source: ClinicalTrials.gov)
Wed Oct 30, 2019 17:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου